Targeting the Leukemia Antigen PR1 with Immunotherapy for the treatment of Multiple Myeloma.

CONCLUSIONS: Collectively, our data demonstrate that PR1 is a novel tumor associated antigen target in MM and that MM is susceptible to immunotherapies that target cross-presented peptides.
PMID: 29661776 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 16, 2018 Category: Cancer & Oncology Authors: Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia RS, Sergeeva A, Yi S, Young KH, Philips AV, Herrmann AC, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ Tags: Clin Cancer Res Source Type: research